Barcelona, Spain – 13th November 2023, Oxolife, the specialist biotech focused on enhancing embryo implantation in women … [Read more...] about Oxolife Appoints International Fertility Experts to its Scientific Advisory Board
Oxolife and its phase II asset OXO-001 for embryo implantation have been featured in the UK's highest circulated daily … [Read more...] about OXO-001, for embryo implantation makes headlines in the Daily News!
We are delighted to share the interview to our CEO Agnès Arbat on #Lideratges, Ariadna’s Belver Comin program, where … [Read more...] about Oxolife in the radio
After a year since the start of our clinical trial and after the last milestone of end of recruitment, we want to share … [Read more...] about At OXOLIFE we are celebrating!!
These days the OXOLIFE team is in Milan (Italy) at European Society of Human Reproduction and Embryology (ESHRE) … [Read more...] about Oxolife attend to ESHRE Congress 2022
After 9 months of recruiting women who are looking for pregnancy, we have finally passed our milestone with 403 patients … [Read more...] about At @OXOLIFE we are celebrating!
Our CEO Agnes Arbat is interviewed at IB radio to talk about our OXOART2 Clinical trial. She explains the potential of … [Read more...] about Oxolife in the News
The biotechnology company Oxolife S.L. (Spain), the Energy Balance, Puberty and Reproductive Health research group of … [Read more...] about Oxolife initiates a collaboration with the University of Cordoba and Rutgers, The State University of New Jersey, to develop a treatment to improve women’s fertility
We are delighted to announce that OXOART2, the OXO-001 phase II clinical trial, has already started! As mentioned by … [Read more...] about ANOTHER BIG MILESTONE FOR OXOLIFE
On the 9th of September, we had the pleasure to meet the Czech and Polish investigators in the OXOART2 Investigators … [Read more...] about Good feelings in the investigators meetings